Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome

References

• Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126(4):454–462.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16):1052–1057.
   PubMed Web of Science ®Google Scholar
• Roberts A, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clin Pharmacol Ther. 2017;101(1):89–98.
   PubMed Web of Science ®Google Scholar
• Khan N, Kahl B. Targeting BCL-2 in hematologic malignancies. Target Oncol. 2018;13(3):257–267.
   PubMed Web of Science ®Google Scholar
• Korycka-Wolowiec A, Wolowiec D, Kubiak-Mlonka A, et al. Venetoclax in the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2019;15(5):353–366.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215–3224.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Davids MS. The development and current use of BCL-2 inhibitors for the treatment of chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12(1):11–19.
   PubMed Web of Science ®Google Scholar
• Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J. 2018;8(10):93.
   PubMedGoogle Scholar
• Halfdanarson TR, Hogan WJ, Moynihan TJ. Oncologic emergencies: diagnosis and treatment. Mayo Clin Proc. 2006;81(6):835–848.
   PubMed Web of Science ®Google Scholar
• Klemencic S, Perkins J. Diagnosis and management of oncologic emergencies. West J Emerg Med. 2019;20(2):316–322.
   PubMed Web of Science ®Google Scholar
• Chapter 4: tumor lysis syndrome [Internet]. Washington (DC): American Society of Nephrology; 2022 [cited 2022 Feb 08]. Available from: https://www.asn-online.org/education/distancelearning/curricula/onco/
   Google Scholar
• Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854.
   PubMed Web of Science ®Google Scholar
• DailyMed – VENCLEXTA – venetoclax kit VENCLEXTA – venetoclax tablet, film coated [Internet]. Bethesda (MD): National Library of Medicine; 2022 [cited 2022 Feb 08]. Available from: https://dailymed.nlm.nih.gov/dailymed/
   Google Scholar
• Gribben JG. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020;188(6):844–851.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Jones JA, Wierda WG, Choi MY, et al. Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. J Clin Oncol. 2016;34(15_Suppl.):7519.
   Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax–rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269–277.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371–4379.
   PubMed Web of Science ®Google Scholar
• Gentile M, Petrungaro A, Uccello G, et al. Venetoclax for the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26(11):1307–1316.
   PubMed Web of Science ®Google Scholar
• Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511–1517.
   PubMed Web of Science ®Google Scholar
• Roeker LE, Fox CP, Eyre TA, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res. 2019;25(14):4264–4270.
   PubMed Web of Science ®Google Scholar
• Chen KY, Brunk KM, Patel BA, et al. Pharmacists’ role in managing patients with chronic lymphocytic leukemia. Pharmacy. 2020;8(2):52.
   Web of Science ®Google Scholar
• Felton MA, Londen G, van Marcum ZA. Medication adherence to oral cancer therapy: the promising role of the pharmacist. J Oncol Pharm Pract. 2016;22(2):378–381.
   PubMed Web of Science ®Google Scholar
• Ma CS. Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting. Integr Pharm Res Pract. 2014;3:11–24.
   Google Scholar
• Scope of hematology/oncology pharmacy practice [Internet]. Chicago (IL): Hematology/Oncology Pharmacy Association; 2013 [cited 2022 Feb 08]. Available from: https://www.hoparx.org/resources/guidelines-standards-summaries
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [Internet]. Washington (DC): U.S. Department of Health and Human Services; 2017 [cited 2022 Feb 08]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50
   Google Scholar
• Valgus JM, Faso A, Gregory KM, et al. Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center. Am J Health Syst Pharm. 2011;68(7):613–619.
   PubMed Web of Science ®Google Scholar
• Scott MA, Heck JE, Wilson CG. The integral role of the clinical pharmacist practitioner in primary care. N C Med J. 2017;78(3):181–185.
   PubMedGoogle Scholar
• Wierda WG, Tambaro FP. How I manage CLL with venetoclax-based treatments. Blood. 2020;135(17):1421–1427.
   PubMed Web of Science ®Google Scholar